Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,397 across all filing types
Latest filing 2023-02-28 Investor Presentation
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Morgan Stanley, European MedTech & Services Conference
Investor Presentation Classification · 98% confidence The document is a presentation titled "#FutureFresenius – Advancing Patient Care" given at the "Morgan Stanley, European MedTech & Services Conference" on February 28, 2023. It reviews FY/22 results, provides an outlook for FY/23, and details the long-term '#FutureFresenius' strategy. It contains detailed financial figures, segment performance reviews (Kabi, Helios), outlook targets, and capital efficiency metrics. This structure—a detailed presentation covering past performance, current strategy, and future guidance, typically delivered to investors or analysts—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a short announcement (RPA) or a transcript (CT).
2023-02-28 English
Conference Call FY 2022, Fresenius
Investor Presentation Classification · 97% confidence The document text is extensive (over 35,000 characters) and contains detailed financial performance reviews for FY/22, outlooks for FY/23, strategic plans ('#FutureFresenius'), segment performance (Kabi, Helios), and specific financial tables (Revenue, OCF, Capex, EBIT margins). This level of detail, covering a full fiscal year and forward-looking guidance, strongly indicates a comprehensive annual report or a document closely associated with it, such as an Investor Presentation or Management Discussion & Analysis (MDA) that often accompanies the 10-K filing. However, the structure, which includes 'Financial review FY/22' and 'Financial priorities & Outlook FY/23' presented as a detailed strategic update and presentation slides, is highly characteristic of an Investor Presentation (IP) or a detailed Management Discussion & Analysis (MDA) that might be filed separately or included within the 10-K. Given the presentation format (headings, bullet points, financial tables summarizing the year) and the focus on strategy and outlook following the annual results, 'Investor Presentation' (IP) is the most fitting specific category, as it is a detailed document for investors summarizing the year and future strategy, distinct from the formal 10-K filing itself, but more detailed than a simple Earnings Release (ER). The document is clearly not a short announcement (ruling 2).
2023-02-22 English
Fresenius SE & Co. KGaA: Outlook 2023 Fresenius advances with deconsolidation of Fresenius Medical Care by changing its legal form into a German stock corporation (Aktiengesellschaft)
Regulatory Filings Classification · 95% confidence The document is dated February 21, 2023, and is classified as an 'Ad-hoc' announcement disclosing 'inside information' according to MAR Regulation (EU) No 596/2014. It primarily discusses strategic decisions, including setting the 2023 outlook (revenue and EBIT guidance) and a major corporate action: the planned deconsolidation of Fresenius Medical Care via a change of legal form. This type of announcement, which provides key financial guidance and strategic updates outside of a formal periodic report (like 10-K or IR), fits best under the 'Earnings Release' (ER) category if it were purely results-focused, or 'Capital/Financing Update' (CAP) due to the legal form change. However, since it is an early announcement of future outlook/guidance and strategic corporate action, it is often categorized as a general regulatory announcement or a specific strategic update. Given the options, it is not a full report (10-K, IR), a transcript (CT), or a director dealing (DIRS). It is a strategic update combined with preliminary guidance. Since it is an 'Ad-hoc' disclosure of forward-looking statements and strategic corporate restructuring, and it is not a formal earnings release (ER) which usually contains actual period results, the most appropriate general category for significant, non-standard regulatory news that doesn't fit elsewhere is 'Regulatory Filings' (RNS), or potentially 'Capital/Financing Update' (CAP) due to the legal form change. Given the emphasis on the 2023 outlook and strategic direction, and the nature of the MAR disclosure, RNS serves as the best general regulatory catch-all for significant, non-periodic news.
2023-02-21 English
Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms review of deconsolidation of Fresenius Medical Care through change of legal form into a stock corporation
Regulatory Filings Classification · 99% confidence The document is dated February 9, 2023, is labeled 'Ad-hoc', and discloses 'inside information acc. to Article 17 MAR'. It discusses a strategic review, specifically analyzing the deconsolidation of a subsidiary (FMC) through a change of legal form. This is a material, non-public event disclosure required under EU regulations (MAR). It is not a standard periodic report (10-K, IR), a specific shareholder action (AGM-R, DVA), or a management/board change (MANG). Since it is a mandatory, immediate disclosure of significant corporate action under regulatory requirements that doesn't fit the other specific categories (like M&A, Financing, or Director's Dealing), it falls best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous regulatory announcements not covered elsewhere. Given its nature as an immediate regulatory disclosure (Ad-hoc/MAR 17), RNS is the most appropriate fit.
2023-02-09 English
Entsprechenserklärung der Fresenius SE & Co. KGaA vom 20. Dezember 2022
Governance Information Classification · 99% confidence The document is titled "Erklärung des Vorstands der persönlich haftenden Gesellschafterin der Fresenius SE & Co. KGaA, der Fresenius Management SE, und des Aufsichtsrats der Fresenius SE & Co. KGaA zum Deutschen Corporate Governance Kodex gemäß § 161 AktG". This explicitly states it is a declaration regarding the German Corporate Governance Code (DCGK). This type of declaration, detailing compliance or non-compliance with governance recommendations, directly corresponds to the definition of Governance Information (CGR). It is not an Annual Report (10-K), an Audit Report (AR), or a general Regulatory Filing (RNS).
2022-12-20 German
Declaration of Conformity of Fresenius SE & Co. KGaA as of December 20, 2022
Governance Information Classification · 99% confidence The document is explicitly titled a 'Declaration by the Management Board... and by the Supervisory Board... on the German Corporate Governance Code pursuant to Section 161 German Stock Corporation Act'. It discusses compliance with the recommendations of the German Corporate Governance Code, including specific sections like C.5 regarding 'overboarding' of board members. This content directly relates to the company's internal rules, board structure, and governance practices, making it a Governance Information document.
2022-12-20 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.